Cross-species comparisons of the pharmacokinetics of ibudilast

Xenobiotica

Volumn 39, Issue 12, 2009, Pages 964-977

  Sanftner, L M ^a   Gibbons, J A ^b   Gross, M I ^a   Suzuki, B M ^a   Gaeta, F C A ^c   Johnson, K W ^a  

^a Avigen Inc   (United States)

^b Jacqueline Gibbons Consulting   (United States)

^c Gaeta Consulting   (United States)

Author keywords

Animals; Ibudilast; Metabolism; Pharmacokinetics; Tolerability

Indexed keywords

6,7 DIHYDRODIOL IBUDILAST; CARBAMAZEPINE; DIPHENHYDRAMINE; DRUG METABOLITE; IBUDILAST; PINATOS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DELAYED DRUG RELEASE; DOG; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; INTERSPECIFIC HYBRID; INTESTINE; LIVER MICROSOME; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; MINIPIG; MONKEY; MOUSE; NONHUMAN; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; PLASMA PROTEIN BINDING; PORTAL VEIN; RABBIT; RAT; SINGLE DRUG DOSE; SPECIES COMPARISON; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINES; LIVER; MALE; MICROSOMES, LIVER; ORGAN SPECIFICITY; PROTEIN BINDING; PYRIDINES; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; MACACA FASCICULARIS; MUS; ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 70849126672     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903254340     Document Type: Article

References (41)

1. Agrawal AK, Shapiro BH. (2003). Constitutive and inducible hepatic cytochrome P450 isoforms in senescent male and female rats and response to low-dose phenobarbital. Drug Metab Disposit 31:612-619
2. Ayrton A, Morgan P. (2001). Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497
3. Bergheim I, Bode C, Parlesak A. (2005). Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin Pharmacol 5:4
4. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, Ulrich RG, Slatter JG. (2006). Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36:963-988
5. Burchell B, Coughtrie MW. (1989). UDP-glucuronosyltransferases. Pharmacol Ther 43:261-289
6. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharmaceut Res 23:1675-1686
7. Collier AC, Tingle MD, Keelan JA, Paxton JW, Mitchell MD. (2000). A highly sensitive fluorescent microplate method for the determination of UDP-glucuronosyl transferase activity in tissues and placental cell lines. Drug Metab Disposit 28:1184-1186
8. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharmaceut Res 10:1093-1095
9. Ding X, Kaminsky LS. (2003). Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Ann Rev Pharmacol Toxicol 43:149-173
10. Kawanokuchi J, Mizuno T, Kato H, Mitsuma N, Suzumura A. (2004). Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology 46:734-742
11. Kishi Y, Ohta S, Kasuya N, Sakita S, Ashikaga T, Isobe M. (2001). Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovasc Drug Rev 19:215-225
12. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. (2007). Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Exp Opin Investig Drug 16:935-950
13. Ledeboer A, Liu T, Shumilla JA, Mahoney JH, Vijay S, Gross MI, Vargus JA, Sultzbaugh L, Claypool MD, Sanftner LM, Watkins LR, Johnson KW. (2006). The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol 2:279-291
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
15. Lu C, Li AP. (2001). Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem-Biol Interact 134:271-281
16. Maeda S, Ishida R, Komuro M, Ohmuro S, Hashimoto H, Hotta M, Uchida H. (1989). Studies of KC-404 (3-isobutyryl-2-isopopylpyrazolo-[ 1,5-apyridine) pharmacokinetics in humans (Report 2). Kiso to Rinsho 23:183-189 [in Japanese]
17. Marchand F, Perretti M, McMahon SB. (2005). Role of the immune system in chronic pain. Nat Rev Neurosci 6:521-532
18. Martignoni M, Groothuis GM, De Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYPmediated drug metabolism, inhibition and induction. Exp Opin Drug Metab Toxicol 2:875-894
19. Matsubara T, Koike M, Touchi A, Tochino Y, Sugeno K. (1976). Quantitative determination of cytochrome P-450 in rat liver homogenate. Ann Biochem 75:596-603
20. McGinnity DF, Collington J, Austin RP, Riley RJ. (2007). Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 8:463-479
21. Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Suzumura A. (2004). Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 46:404-411
22. Moalem G, Tracey DJ. (2006). Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev 51:240-264
23. Nagatsu Y, Higuchi T, Hirobe M. (1990). Application of chemical P-450 model systems to study drug metabolism. III. Metabolism of 3-isobutyryl-2- isopropylpyrazolo[1,5-alpha]pyridine. Chem Pharmacol Bull (Tokyo) 38:400-403
24. Ohe T, Sato M, Tanaka S, Fujino N, Hata M, Shibata Y, Kanatani A, Fukami T, Yamazaki M, Chiba M, Ishii Y. (2003). Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio. Drug Metab Disposit 31:1251-1254
25. Peterson GL. (1979). Review of the Folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall. Ann Biochem 100:201-220
26. Plopper CG, Weir AJ, Morin D, Chang A, Philpot RM, Buckpitt AR. (1993). Postnatal changes in the expression and distribution of pulmonary cytochrome P450 monooxygenases during Clara cell differentiation in rabbits. Mol Pharmacol 44:51-61
27. Pustylnyak VP, Lebedev AN, Gulyaeva LF, Lyakhovich VV, Slynko NM. (2007). Comparative study of CYP2B induction in the liver of rats and mice by different compounds. Life Sci 80:324-328
28. Rolan P, Gibbons JA, He L, Chang E, Jones D, Gross MI, Davidson JB, Sanftner LM, Johnson KW. (2008). Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. Br J Clin Pharmacol 66:792-801
29. Schuetz EG, Schuetz JD, May B, Guzelian PS. (1990). Regulation of cytochrome P-450b/e and P-450p gene expression by growth hormone in adult rat hepatocytes cultured on a reconstituted basement membrane. J Biol Chem 265:1188-1192
30. Sonderfan AJ, Arlotto MP, Dutton DR, McMillen SK, Parkinson A. (1987). Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys 255:27-41
31. Suzumura A, Ito A, Yoshikawa M, Sawada M. (1999). Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res 837:203-212
32. Takagi KEK, Nagatsu Y. (1985). Studies on the metabolic fate of 3-isobutyryl-2-isopropyl yrazolo(1,5-a) pyridine (KC-404). 1. Absorption, distribution and excretion in rats, dogs, and monkeys. Oyo Yakuri 30:967-981
33. Uchida O, Ohmuro S, Hashimoto H, Irikura T. (1985). Pharmacokinetics and metabolism of 3-isobutyryl-2-isopropylpyrazolo [1,5-a] pyridine (KC-404) in humans. Kiso to Rinsho 19:42-50. [in Japanese]
34. Ullrich D, Bock KW. (1984). Glucuronide formation of various drugs in liver microsomes and in isolated hepatocytes from phenobarbital-and 3-methylcholanthrene-treated rats. Biochem Pharmacol 33:97-101
35. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. (2005). Glia: novel counter-regulators of opioid analgesia. Trend Neurosci 28:661-669
36. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. (2007). Norman Cousins Lecture. Glia as the 'bad guys': implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immunit 21:131-146
37. Watkins LR, Maier SF. (2003). Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Disc 2:973-985
38. Winsnes A. (1969). Studies on the activation in vitro of glucuronyltransferase. Biochim Biophys Acta 191:279-291
39. Yamada H, Ishii Y, Yamamoto M, Oguri K. (2006). Induction of the hepatic cytochrome P450 2B subfamily by xenobiotics: research history, evolutionary aspect, relation to tumorigenesis, and mechanism. Curr Drug Metab 7:397-409
40. Yamazoe Y, Shimada M, Murayama N, Kato R. (1987). Suppression of levels of phenobarbital-inducible rat liver cytochrome P-450 by pituitary hormone. J Biol Chem 262:7423-7428
41. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. (1999). Characterization of human small intestinal cytochromes P-450. Drug Metab Disposit 27:80409